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Abstract
Acquired resistance to vemurafenib develops through reactivation of RAF/MEK/ERK signaling or 
bypass mechanisms. Recent combination therapies such as a MEK inhibitor combined with 
vemurafenib show improvement in major clinical end points but the percentage of patients with 
adverse toxic events is higher than with vemurafenib monotherapy and most patients ultimately 
relapse. Therefore, there is an urgent need to develop new anti-melanoma drugs and/or adjuvant 
agents for vemurafenib therapy. In this study, we created a novel semi-organically modified 
derivative, DETD-35, from deoxyelephantopin (DET), a plant sesquiterpene lactone demonstrated 
as an anti-inflammatory and anti-mammary tumor agent. Our results show that DETD-35 inhibited 
proliferation of a panel of melanoma cell lines, including acquired vemurafenib resistance A375 
cells (A375-R) established in this study, with superior activities to DET and no cytotoxicity to 
normal melanocytes. DETD-35 suppressed tumor growth and reduced tumor mass as effectively as 
vemurafenib in A375 xenograft study. Furthermore, DETD-35 also reduced tumor growth in both 
acquired (A375-R) and intrinsic (A2058) vemurafenib resistance xenograft models, where 
vemurafenib showed no anti-tumor activity. Notably, the combination of DETD-35 and 
vemurafenib exhibited the most significant effects in both in vitro and in vivo xenograft studies 
due to synergism of the compound and the drug. Mechanistic studies suggested that DETD-35 
overcame acquired vemurafenib resistance at least in part through deregulating MEK-ERK, Akt, 
and STAT3 signaling pathways and promoting apoptosis of cancer cells. Overall, our results 
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suggest that DETD-35 may be useful as a therapeutic or adjuvant agent against BRAFV600E 
mutant and acquired vemurafenib resistance melanoma.
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Introduction
Melanoma is the most lethal form of skin cancer and cases are increasing year by year. In 
the United States, the estimated number of new melanoma cases in 2001 was 51,400. This 
figure grew by 43.7% to 73,873 cases in 2015 (1, 2). Mutation in BRAF, V-raf murine 
sarcoma viral oncogene homolog B1 protein, BRAFV600E is found in approximately 50% of 
melanoma patients and drives RAF/MEK/ERK mitogen-activated protein kinase (MAPK) 
signaling to promote cancer progression (3). Therefore, a number of inhibitors targeting 
BRAF mutation or MAPK signaling have been developed. For example, vemurafenib 
(PLX4032), a small molecule specifically targeting BRAFV600E mutation, was discovered 
by Plexxikon in 2008 (4), and received FDA approval for treatment of late-stage melanoma 
in 2011 due to its promising clinical efficacy. Unfortunately, patients developed drug 
resistance and eventually relapsed within an average of 7 months after vemurafenib therapy 
(5). Acquired resistance to PLX4032 in human melanoma was mainly through paradoxical 
activation of MAPK signaling or bypass mechanisms (6–11). The reactivation of MEK-ERK 
signaling is driven by either a RAF-independent pathway through overexpression of MAP 
kinase 8 (MAP3K8, or COT) or the activation of the receptor tyrosine kinases (RTKs) (12–
14). RTK signaling is initially suppressed by the elevated state of ERK-dependent feedback 
in BRAFV600E mutant melanoma cells in which RAS activity is low and BRAFV600E 
functions as a monomer. Upon vemurafenib treatment, inhibition of ERK activity relieves 
ERK-dependent feedback and allows ligand-dependent signaling by growth factors, leading 
to a rebound in RAS activity that promotes the formation of RAF dimers and reactivation of 
MEK-ERK signaling despite the presence of vemurafenib (15). These findings led to clinical 
trials such as a MEK inhibitor combined with vemurafenib or other BRAF inhibitors (16). 
Nonetheless, although recent combination therapy showed improvement in major clinical 
end points, the percentage of patients with adverse toxic events are higher than with 
vemurafenib monotherapy and most patients ultimately relapse (16–18). Therefore, it is 
important to continue to develop new anti-melanoma drugs and/or novel adjuvant 
approaches for vemurafenib therapy.
Elephantopus scaber L. is a traditional Chinese medicine which has been used for various 
inflammation-related syndromes. Our laboratory has isolated a bioactive compound 
deoxyelephantopin (DET) from E. scaber which shows anti-inflammation, hepatoprotective 
and anti-breast cancer activities by modulating multiple mechanisms, such as activation of 
the JNK-mediated apoptotic pathways, deregulation of the IKK/NFκB pathway and the 
ubiquitin proteasome machinery, and impeding TS/A cell motility by inhibiting calpain-
mediated adhesion dynamics and inducing reactive oxygen species and aggresome formation 
(19–22). Based on a structural modeling analysis, we previously observed that the specific 
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carbonyl group at C12, C15 and C16 of DET directly interacts with RelA subunit of NF-κB 
through inter-hydrogen bonding. This interaction between DET and RelA likely averts the 
RelA subunit from binding to its DNA target (20). Notably, DET is also observed to be 
superior to paclitaxel (PTX) in prolonging the lifespan/survival rate in TS/A mammary 
tumor isograft bearing mice (19). In addition, DET has been reported to possess anti-lung 
adenocarcinoma (23), nasopharyngeal carcinoma (24) and human lymphocyte proliferation 
in vitro and anti-ascites tumor in vivo (25). Together, we consider DET as a novel lead 
compound for further modification or optimization of its structure to create a more potent 
drug lead for cancer management. We have thus initiated semi-organic synthesis of DET 
derivatives (DETDs) in order to obtain a potent DETD for melanoma treatment.
In this report, we provide a comprehensive evaluation of the preclinical activity profile of 
DETD-35, a derivative of DET, in BRAFV600E mutant and acquired vemurafenib resistance 
melanoma cells in vitro and in vivo. DET and vemurafenib were also evaluated in parallel. 
We showed that DETD-35 effectively inhibited BRAFV600E mutant and acquired 
vemurafenib resistance xenograft tumor growth in mice, with superior activities to parental 
compound DET. The synergism of DETD-35 and vemurafenib led to better in vitro and in 
vivo efficacy compared to treatment with either agent alone. This study demonstrates the 
novel therapeutic potential of DETD-35 against BRAFV600E mutant and acquired 
vemurafenib resistance in melanoma.
Materials and Methods
Preparation of DET and organic synthesis of DETDs
DET isolation followed the protocol published elsewhere (19). DETD-3 was derived from 
DET by translactonization via the hydrolysis of DET followed by acidic treatment. DETD-5, 
−6, −13, −17, −19, −24, −31, −33, −35, −39, and −43 were further synthesized from 
DETD-3 (26).
Chemicals and reagents
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 
(DMSO), N-acetyl-L-cysteine (NAC) and crystal violet were purchased from Sigma-Aldrich 
(St. Louis, MO). DMEM, fetal bovine serum (FBS), and the antibiotic mixture (penicillin-
streptomycin) were from Invitrogen (Carlsbad, CA, USA). PLX4032 and MEK inhibitor 
(PD0325901) were purchased from Selleck Chemical (Houston, TX). All other solvents or 
chemicals were of reagent or HPLC grade.
Cell lines and culture conditions
Normal human epithelial cell melanocytes (ATCC® PCS-200-012™) and a spectrum of 
wild-type or mutant melanoma cell lines including murine B16-F10 (ATCC® CRL-6475™): 
NRAS mutation and human cell lines MeWo (ATCC® HTB-65™): wild-type, A375 
(ATCC® CRL-1619™) and A2058 (ATCC® CRL-11147™): BRAFV600E mutation, and SK-
MEL-2 (ATCC® HTB-68™): NRAS mutation were obtained from the ATCC (Manassas, 
VA). All cell lines were purchased during 2010–2012 and authenticated originally by ATCC 
using short tandem repeat (STR) analysis. Cells were expanded and frozen down at low 
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passage within 1 month after the receipt of the original stocks. Cells were then thawed and 
used within 15 passages without further authentication for this study. Cells were cultured in 
manufacturers’ suggested medium supplemented with 10% fetal bovine serum, 100 
units/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a humidified 5% CO2 
incubator.
Animals
Female NOD/SCID mice bred in the Laboratory Animal Core Facility (Agricultural 
Biotechnology Research Center, Academia Sinica, Taiwan) were given a standard laboratory 
diet and distilled H2O ad libitum and kept on a 12 h light/dark cycle at 22±2 °C. All 
experimental protocols (No: 11-02-137) were approved by the Institutional Animal Care and 
Utilization Committee, Academia Sinica, Taiwan.
Cell viability assay
Cells were seeded in 96-well plates overnight and treated with compounds for 24 to 72 h. 
Cell growth was determined by MTT-based colorimetric assays according to Scudiero et al. 
(27). Viability of the cells treated with vehicle-only (0.5% DMSO) was defined as 100% 
viability. Survival of cells after treatment with compound or PLX4032 were calculated using 
the following formula: viable cell number (%) = [OD570 (treated cell culture)/OD570 
(vehicle control)] × 100.
Compound-drug combination assay
Concentrations of DETD-35 and PLX4032 for compound-drug combination study were 
selected based on their IC50 values from MTT assay. The Chou-Talalay method was used to 
determine the effects of a compound-drug combination on A375 cells (28). The interaction 
of DETD-35 and PLX4032 was determined by the combination index (CI), and the CI plot 
was generated using CompuSyn software. The combined effects of two compounds can be 
categorized as follows: CI < 1 indicates synergism; CI = 1 indicates an additive effect; CI > 
1 indicates antagonism between the two compounds tested (28).
Colony formation assay
Colony-forming cell growth was obtained by growing A375 or A375-R cells in 24-well 
plates with indicated treatments for 21 days. The medium containing the compound or drug 
was refreshed every three days. Cell colonies were stained with 0.1% (w/v) crystal violet in 
phosphate buffer saline, dried and photographed. Cell-retained crystal violet was extracted 
with 20% (v/v) acetic acid in water and quantitatively measured by absorbance at 595 nm. 
Relative colony-forming percentage in each treatment was compared to the control 
treatment.
Cell cycle analysis
Cell cycle analysis was performed as described by Shyur et al. (29). Cells were synchronized 
by incubation in medium containing 1% FBS for 12 h, and the culture was then incubated 
with fresh medium/10% FBS containing vehicle or compound for 24 h. Both adherent and 
floating cells were collected, washed with PBS and fixed with 1 mL of ice-cold 70% ethanol 
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overnight at 4°C. Cells were stained with propidium iodide/RNase A solution for 30 minutes 
at room temperature in the dark and then analyzed by flow cytometry (Flow cytometer BD 
LSR II).
Apoptosis detection
Cells were seeded in 6-well plates and treated with vehicle or indicated compounds. After 72 
h of incubation, apoptotic cells were analyzed using FITC Annexin V Apoptosis Detection 
Kit (BD Pharmingen) according to the manufacturer’s instructions and flow cytometry.
Western blot analysis
Total cellular proteins were prepared from tested cells as previously described (30). Protein 
concentration was determined by the Bradford method (Bio-Rad). Protein samples were 
resolved by 5% to 20% gradient SDS-PAGE and then underwent immunoblotting. Primary 
antibodies against ERK1/2 (Sc-94), Bax (Sc-20067), Akt (Sc-5298), JNK (Sc-571), c-Jun 
(Sc-1694) and STAT3 (Sc-482) were purchased from Santa Cruz Biotechnology, phospho-
Src (GTX81151) was purchased from GeneTex, Src (2778-1) was purchased from 
Epitomics, phospho-Akt (#4058), phospho-STAT3 (#9131), phospho-MEK (#9121), MEK 
(#9122), phospho-ERK1/2 (#9106), p27 (#2552), cyclin D1 (#2978), BcL-xL (#2764), 
phospho-SAPK/JNK (#9251), phospho-c-Jun (#9261), caspase 7 (#9492), cleaved caspase 7 
(#9491), PARP (#9542), and cleaved PARP (#5625) were purchased from Cell Signaling 
Technology, and actin (MAB1501) was purchased form Merck Millipore. Appropriate 
horseradish peroxidase-conjugated secondary antibodies were used. Protein bands reacting 
to specific antibodies were visualized by use of enhanced chemiluminescence (Amersham) 
with exposure to chemiluminescence light film (BioMax; Kodak Co.). The resulting images 
were quantified by densitometry using Bio-Profil (Bio-1D 97.04, Vilber-Lourmat).
Caspase-3 activity assay
Caspase-3 activity was detected using NucView 488 Caspase-3 Assay Kit for Live Cells 
(Biotium, Catalog No. 30029). Briefly, A375 and A375-R cells were seeded in 10 cm plates, 
treated with vehicle or compound for 72 h, and then the cells were trypsinized and 
resuspended at a density of 1 × 106 cells/mL. Cell suspension (0.2 mL) was pipetted into a 
test tube and incubated with a 5 µM NucView 488 substrate concentration for 30 min at 
room temperature in the dark. After that, 300 µL of PBS was added into each test tube and 
analyzed by flow cytometry. The intensity of the fluorescence was measured at an excitation 
wavelength of 485 nm and an emission wavelength of 515 nm.
Measurement of reactive oxygen species (ROS)
ROS level in the cells was measured using Total ROS Detection Kit (Enzo, Catalog No. 
51011). Briefly, A375 and A375-R cells were seeded in 10 cm plates for 18 h. Cells were 
pretreated with or without 5 mM NAC for 1 h before treating with vehicle or compounds for 
2 h. The cells were then trypsinized and resuspended in 500 µL of ROS detection solution 
which can be reacted to a wide range of reactive species, such as hydrogen peroxide, 
peroxynitrite, hydroxyl radicals, nitric oxide and peroxy radical, yielding a green fluorescent 
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product, and incubated for 30 min at 37 °C. The generated ROS level was then analyzed by 
flow cytometry.
In vivo xenograft tumor models
A375, A375-R or A2058 cells (3 × 106) were injected subcutaneously to the flanks of 6-
week-old NOD/SCID mice. Once the tumor volume reached around 50 mm3, the mice were 
randomized into treatment groups (n = 8 per group) and the treatments were started. Body 
weight and tumor volume of the mice were recorded every three days using formula a × b2 × 
0.5, where a and b represent the larger and smaller tumor diameters (31). Tumor growth 
inhibition (TGI) was calculated as 100 × [1 − (mean tumor volume final − mean tumor 
volume initial) treatment group/(mean tumor volume final − mean tumor volume 
initial) vehicle group] (31).
Immunohistochemistry analysis
The formalin-fixed and paraffin-embedded tumor sections (4 µm thick) were heat 
immobilized and deparaffinized with xylene and rehydrated in a graded series of ethanol 
with a final wash in distilled water. Antigen retrieval involved use of Target Retrieval 
Solution (DakoCytomation, Glostrup, Denmark) in a Decloaking Chamber (Biocare 
Medical, Walnut Creek, CA). The following antibodies were used for immunohistochemistry 
analysis: phospho-Src (GTX81151) from GeneTex, phospho-Akt (#4060), phospho-MEK 
(#2338), phospho-ERK1/2 (#4370), Ki-67 (#9027), cleaved caspase-3 (#9661), and cleaved 
PARP (#5625) from Cell Signaling Technology.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analyses were conducted using an SAS 
program (SAS Institute), and significant differences within treatments were determined by 
ANOVA. P values of less than 0.05 were considered statistically significant.
Results
DET and DETDs inhibit melanoma cell proliferation in vitro
DET had an anti-proliferative effect on human A375 or mouse B16-F10 melanoma cells at 
an IC50 value of 6.0 µM; however, the re-lactonized derivative DETD-3 did not show anti-
melanoma cell proliferation activity within the same tested concentration up to 10 µM (Table 
1). Thus, the hydroxyl group at the C-6 position in DETD-3 was further modified to improve 
the activity and/or study the structure-activity relationship. Attaching an acyl group on the 
C-6 hydroxyl group can produce an ester, which may act not only as a prodrug, but also 
influence the interaction of the drug. An additional acyl group might provide an H-bond 
acceptor, of appropriate size to fill in the cavity space of the protein binding site, with decent 
hydrophobicity, and so on. The aliphatic groups of various sizes were connected to produce 
DETD-17, −5, −13, −19, and −24. An aromatic group offers a planarity and π-electron rich 
space, which may play an important role in ligand-protein interaction. Therefore, benzoyl, 
phenyl acetoxyl, and cinnamoyl groups were also connected to the C-6 hydroxyl to produce 
DETD-31, −33, −43, −35, −6 and −39, respectively. These ester derivatives could have 
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various distances between the aromatic ring and the terpene skeleton. Chemical structures of 
DET and DETDs are shown in Table 1.
All synthesized DETDs together with the parental phytocompound DET as a reference were 
evaluated for anti-melanoma cell proliferation activity using wild-type as well as mutant 
melanoma cell lines B16-F10, MeWo, A375, A2058, SK-MEL-2, and normal melanocytes. 
DET only inhibited B16-F10 and A375 cell proliferation, but showed no detectable activities 
against other human melanoma cells at tested concentrations up to 10 µM. Among DETDs 
with aliphatic ester groups, only DETD-5 showed comparable antiproliferative activities 
against the tested melanoma cells, except wild-type MeWo and normal melanocytes, with 
IC50 values of 4.1–7.8 µM. Other aliphatic ester derivatives, such as DETD-17, −13, −19, 
and −24, did not show inhibitory effects on any of the tested human melanoma cells. 
Compared to aliphatic ester derivatives, interestingly, most DETDs with the aromatic ester 
group inhibited the melanoma cell growth without affecting normal cells. Aromatic ester 
derivatives, DETD-33, −35, −6 and −39, inhibited all tested melanoma cell proliferation 
with IC50 values of 3.9–9.9, 2.2–6.7, 2.5–6.0, and 1.6–3.5 µM, respectively. Particularly, 
DETD-35 with 10π electronic naphthalene group and DETD-39 with 3-methoxycinnamate 
group demonstrated two times more potent anti-proliferation against the tested melanoma 
cells than DET itself. These results indicate that the feature of the aromatic ring on the ester 
group is favored for the anti-melanoma activity and more electron rich systems tend to be 
more potent. DETD-39 is slightly cytotoxic to normal human melanocytes with an IC50 of 
9.0 µM (Table 1), while DETD-35 was demonstrated to have little or no toxicity to normal 
melanocytes, with only 9.1% inhibition detected at 10 µM concentration. Therefore, we 
chose DETD-35 for further investigation.
DETD-35 shows synergism with vemurafenib in inhibiting A375 cell proliferation
Compound-drug combination assay was carried out to evaluate the potential synergism 
between vemurafenib and DETD-35. The MTT-based anti-proliferation assay showed that 
the IC50 of PLX4032 and DETD-35 on A375 cells were 0.07 and 0.85 µM, respectively, 
when 2 × 103 cells were initially seeded and treated with the compound for 72 h (Fig. 1A 
and B). A greater dose-dependent cytotoxicity of DETD-35 to A375 cells was observed at 
the tested compound concentrations up to 20 µM in which less than 10% viable cells were 
detected (data not shown). MTT assay with a fixed concentration of PLX4032 (10 nM) 
combined with increasing concentrations of DETD-35 (0.1 to 1 µM) showed better 
inhibition compared to DETD-35 treatment alone at the same tested concentrations (Fig. 
1C). The CI values calculated using CalcuSyn software for combination treatment of 
DETD-35 and vemurafenib were within 0.60 to 1.05, indicating either synergism or an 
additive effect of the compound-drug combination (Fig. 1D).
We also evaluated the long-term anti-proliferative effects of DETD-35 and PLX4032 
(treatment for 21 days) using colony formation assay. The parental compound DET was also 
evaluated in parallel. PLX4032 inhibited colony formation of A375 cells, with 55% 
inhibition at 0.1 µM treatment. DETD-35 or DET alone also showed inhibition in a dose-
dependent manner. Of note, cells treated with DETD-35 at 0.5 µM, 1.25 µM and 2.5 µM 
inhibited 42%, 71% and 98% colony formation, respectively, and 1 µM, 2.5 µM and 5 µM of 
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DET treatment inhibited 38%, 65% and 91% colony formation, respectively, of A375 cells. 
Importantly, the combination treatment displayed better effects than the individual 
compound or drug treatment. At 0.1 µM PLX4032 plus 1.25 µM DETD-35 or 2.5 µM DET, 
the inhibition reached 88% and 81%, respectively (Fig. 1E). The anti-proliferative effect of 
PLX4032 was strongly associated with induction of G1-phase cell-cycle arrest (Fig. 2F). 
DETD-35 did not have any significant effect on A375 DNA distribution in the cell-cycle, 
while DET at 5 µM induced G2/M-phase arrest (Fig. 1F). Both DETD-35 and DET 
treatment induced high levels of A375 cell apoptosis, up to 85.2% and 67.8%, respectively; 
however, PLX4032 treatment only induced 10.4% apoptosis in the cells (Fig. 1G). We found 
that the profound effect of PLX4032 on inducing G1-phase cell-cycle arrest dominated the 
effect of compound (DETD-35 or DET)-drug combination in A375 cells, whereas DETD-35 
or DET-sensitized PLX4032 induced A375 cell apoptosis to 91% and 69%, respectively 
(Fig. 1F and G).
DETD-35 deregulates MEK-ERK signaling and induces apoptotic hallmarks in A375 cells
Next, we investigated the underlying mechanisms by which DET, DETD-35 and PLX4032 
inhibited A375 melanoma cell activity. We observed that PLX4032 inhibited MEK and ERK 
phosphorylation, increased p27 expression and suppressed cyclin D1 expression as shown 
by western blotting (Fig. 2A). DETD-35 or DET also inhibited MEK and ERK 
phosphorylation, but had no effect on p27 and cyclin D1 expression; however, both 
compounds induced the apoptotic hallmarks, the cleaved form of PARP accumulation and 
caspase-3 activity in the cells (Fig. 2A and B). The compound-drug combination showed 
inhibition of pMEK, pERK and cyclin D1 expression as well as induction of p27 and 
cleaved PARP protein levels (Fig. 2A), and caspase-3 activity (Fig. 2B), indicating 
combination treatment integrated the effects of PLX4032 and DET or DETD-35 in A375 
cells. Other apoptotic markers Bax and BcL-xL were not responsive to PLX4032, DET or 
DETD-35 treatment.
DETD-35 alone or in combination with vemurafenib suppresses tumor growth in an A375 
orthotopic xenograft model
We used an A375 human melanoma xenograft model to further evaluate the in vivo 
bioefficacy of DET, DETD-35, PLX4032 and the compound-drug combination. 
Supplementary Figure S1A displays the detailed experimental design for A375 xenograft 
study. Figure 3A shows representative tumor tissues from the tumor control and treatment 
groups of the A375 xenograft study. PLX4032 (20 mg/kg/day, 24 doses in total) was 
effective in suppressing tumor growth with 87.4% tumor growth inhibition (TGI) and 
reduction of tumor mass by 71.9%. We observed that DETD-35 and DET (20 mg/kg/every 
two days, 12 doses in total) also suppressed tumor growth with 87.1% and 71.0% TGI and 
reduced tumor mass by 70.5% and 47.5%, respectively (Fig. 3B and C), indicating 
DETD-35 was as effective as vemurafenib and possessed better anti-melanoma growth 
activity than DET. Importantly, the compound-drug combination in which DETD-35 (20 
mg/kg/every four days, 6 doses in total) and PLX4032 (20 mg/kg/every two days, 12 doses 
in total) were administered alternately and the treatment frequency was only half of the 
single compound administration frequency, showed similar anti-tumor efficacy as the single 
agent treatment (91.0% TGI and 72.3% reduction in tumor mass), suggesting synergism of 
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DETD-35 and PLX4032 in mice (Fig. 3B and C). In addition, there were no indications of 
toxicity such as body weight loss or changes in organ index in the treatment groups 
(Supplementary Fig. S1B and C). Immunohistochemical analysis showed PLX4032 
significantly inhibited pMEK, pERK and proliferation marker Ki-67 levels, and slightly 
induced the apoptotic markers, i.e., cleaved caspase-3 and cleaved PARP levels in the tumor 
tissues (Fig. 3D). We observed that DETD-35 and DET also significantly inhibited pMEK, 
pERK and Ki-67 levels in which the inhibitory effect of DETD-35 was significantly better 
than DET (Fig. 3D). Moreover, both compounds showed stronger induction of cleaved 
caspase-3 and cleaved PARP levels compared to PLX4032 treatment. Importantly, we found 
that the compound-drug combination reduced levels of pMEK, pERK and Ki-67 as did 
PLX4032 and induced levels of cleaved caspase-3 and cleaved PARP as did DETD-35 (Fig. 
3D). These results were in good agreement with results observed in the in vitro studies.
DETD-35 overcomes acquired vemurafenib resistance in vitro
To study whether or not DETD-35 could overcome acquired resistance to BRAF inhibitor in 
A375 cells, we first generated the A375 cell line which was resistant to PLX4032 (A375-R) 
as previously reported (10). Briefly, A375 melanoma cells were seeded in T75 plates and 
treated with increasing concentrations of PLX4032 (10, 20, 50, 100, 250, 500, 1000, 2000, 
5000 nM) through approximately 2 months and 20 passages. We have successfully 
developed acquired resistance cell line A375-R which is 100-fold less sensitive to PLX4032 
treatment compared to parental cell line (IC50: 7.34 vs. 0.07 µM). Importantly, DETD-35 
and DET were still effective against the resistance cell line (Fig. 4A, B and C). PLX4032 
revealed no inhibitory effect on colony formation whereas DETD-35 and DET inhibited 
colony formation of A375-R cells in a dose dependent manner (Fig. 4D). Moreover, the 
compound-drug combination showed dramatic inhibition of A375-R cell colony formation, 
indicating DETD-35 or DET could sensitize the anti-proliferative effect of PLX4032 (Fig. 
4D). Consistent with the anti-proliferation results, PLX4032 had no effect on cell-cycle 
distribution and apoptosis of A375-R cells. DETD-35 had no effect on cell-cycle distribution 
whereas DET caused G2/M-phase cell-cycle arrest in A375-R cells. Furthermore, both DET 
and DETD-35 induced high-levels of (86∼89%) apoptosis in A375-R cells (Supplementary 
Fig. S2A and B). For mechanistic studies, we included MEK inhibitor combined with 
PLX4032 as a positive control since MEKi combination with vemurafenib is used to treat 
BRAFV600E melanoma patients clinically (16). We found that PLX4032 inhibited pSrc, 
pMEK, pERK, pAkt and pSTAT3 protein levels in A375 cells. In contrast, phosphoproteins 
were reactivated in PLX4032-treated A375-R cells. Moreover, PLX4032 could not induce 
p27 expression or reduce cyclin D1 level in A375-R cells, in the same as observed in 
PLX4032-treated A375 cells (Fig. 4E). DETD-35 and DET, however, could suppress the 
phosphorylated proteins, suggesting inhibition of their reactivation in resistant A375 cells. 
Both compounds were also observed to induce cleaved PARP expression and caspase-3 
activity in A375-R cells (Fig. 4E and Supplementary Fig. S2C). Compound-drug 
combination with DETD-35 or DET plus PLX4032 also inhibited levels of pSrc, pMEK, 
pERK, pAkt and pSTAT3 proteins, in the same way as the MEK inhibitor+PLX4032 (Fig. 
4E). Interestingly, the compound-drug combination induced cleaved PARP expression 
whereas MEK inhibitor+PLX4032 treatment induced p27 expression and reduced cyclin D1 
expression (Fig. 4E).
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DETD-35 overcomes acquired and intrinsic vemurafenib resistance in vivo
We used A375-R (acquired vemurafenib resistance) and A2058 (intrinsic vemurafenib 
resistance due to lack of PTEN expression) xenograft mouse models to evaluate the in vivo 
bioefficacy of DETD-35, DET, PLX4032 and the compound-drug combination against 
vemurafenib resistance melanoma. Supplementary Figure S3A displays the detailed 
experimental design for A375-R and A2058 xenograft study. Figure 5A shows representative 
tumor tissues from the A375-R xenograft study. PLX4032 treatment (75 mg/kg/day, 24 
doses in total) showed no anti-tumor activity with similar tumor growth rate and sizes 
compared to the tumor control group in both A375-R (Fig. 5B and C) and A2058 (Fig. 5D 
and E) xenograft models, as expected. DETD-35 (20 mg/kg/every two days, 12 doses in 
total) effectively inhibited A375-R (Fig. 5B and C) and A2058 (Fig. 5D and E) tumor 
growth in mice with 47.1% and 73.7% TGI and a reduction in tumor mass of 46.3% and 
69.0%, respectively. DET (20 mg/kg/every two days, 12 doses in total) only inhibited A375-
R tumors with 31.2% TGI (Fig. 5B). Notably, the compound-drug combination in which 
alternate administration of DETD-35 (20 mg/kg/every two days, 12 doses in total) and 
PLX4032 (75 mg/kg/every two days, 12 doses in total) showed the best anti-tumor activity 
in both vemurafenib resistance xenografts A375-R (Fig. 5B and C) and A2058 (Fig. 5D and 
E), with 76.5% and 79.0% TGI and 65.2% and 75.3% reduction in tumor mass, respectively. 
There was no indication of toxicity such as body weight loss or organ index changes in the 
treatment groups (Supplementary Fig. S3B, C, D and E). Consistent with in vitro studies, 
immunohistochemical analyses showed that DETD-35 and DET treatment or the compound-
drug combination significantly reduced pSrc, pMEK, pERK, pAKt and Ki-67 levels, and 
increased cleaved caspase-3 and cleaved PARP levels in A375-R xenograft tissues, but 
PLX4032 alone did not have effect on the expression of these proteins (Fig. 5F). Notably, 
DETD-35 showed more activity than DET, a result which mirrored the observations in the 
A375 xenograft study.
DETD-35 induces generation of reactive oxygen species (ROS) to trigger apoptotic cell 
death in A375 and A375-R cells
Previously, we demonstrated that DET treatment can induce oxidative stress to facilitate the 
activation of the c-Jun N-terminal kinase (JNK) signaling pathway towards apoptotic cell 
death in TS/A cells (19). We evaluated whether DETD-35 exerts the same mechanism by 
inducing ROS-mediated apoptosis in A375 and A375-R cells. We first performed the 
proliferation assay in the cells with or without pretreatment with the ROS scavenger NAC. 
As shown in Figure 6, the 1 µM DETD-35 and 2 µM DET treatment inhibited 59% and 55% 
A375 cell viability and 69% and 65% A375-R cell viability, respectively, and 5 mM NAC 
alone did not affect either type of cell viability (Fig. 6A and B). However, treatment with 
NAC for 1 h before treating with either DET or DETD-35 restored cell viability in both 
A375 and A375-R cells (Fig. 6A and B), suggesting that the presence of ROS is correlated 
to the inhibitory effect of DET or DETD-35 on melanoma cell viability. We then examined 
the ROS levels in the cells treated with DET or DETD-35 using flow cytometry. Treatment 
with 2.5 µM DETD-35 or 5 µM DET for 2 h significantly increased (more than 2-fold) ROS 
level in both A375 and A375-R cells, as indicated by the data in Fig. 6C; this effect could be 
significantly reversed by pretreating the cells with 5 mM NAC for 1 h (Fig. 6C). Because 
oxidative stress can activate JNK, which subsequently induces c-Jun activation and 
Feng et al. Page 10
Mol Cancer Ther. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
phosphorylation to trigger apoptosis in cancer cells (19), we thus further analyzed JNK 
signaling molecules in the cells with the same treatment by western blotting. We observed 
that DETD-35 significantly activated p-c-Jun and c-Jun protein levels at early time points (2, 
4 and 8 h) in both A375 and A375-R cells, and less effect was observed for the DET 
treatment (Fig. 6D). Furthermore, cell apoptosis markers, cleaved forms of caspase-7 (cl-
caspase-7) and PARP (cl-PARP), were strongly induced by DETD-35 and DET treatment at 
a later treatment time point (24 h) in both A375 and A375-R cells (Fig. 6D). Notably, 
pretreatment with 5 mM NAC for 1 h significantly blockaded DETD-35-induced cascade 
protein expression or activation of p-c-Jun/c-Jun, cl-caspase-7 and cl-PARP in both cell 
lines. Interestingly, although DET was also observed to induce ROS production in both cell 
lines and the significant DET-induced apoptosis could be also reversed by NAC 
pretreatment, the activation of p-c-Jun/c-Jun was found much less significant compared to 
that of DETD-35. Together, our results indicate that DETD-35 or DET induced apoptotic 
cell death in A375 and A375-R cells were in part through generation of ROS, yet different 
pathways might be involved in both compound effects.
Discussion
From the early 1980s to 2010, dacarbazine was the only FDA-approved chemotherapeutic 
drug for the treatment of metastatic melanoma with 15% to 20% overall response, 4 to 6 
month of medium response duration, and less than 5% complete response (32). However, 
management of melanoma has improved dramatically in recent years. For example, the 
immunotherapeutic agent ipilimumab which acts against cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4), and targeted therapeutics agents such as vemurafenib and dabrafenib 
(BRAF inhibitor) show a remarkable tumor response rate and prolong patient survival 
leading to a new era of melanoma therapies (33). Unfortunately, melanoma tumors 
frequently relapse due to acquired drug resistance to both immunotherapeutics and targeted 
therapeutics agents; consequently, there is a growing and urgent need to develop novel or 
alternative therapeutic approaches for cutaneous melanoma. In this study, we created a 
phytocompound derivative DETD-35 and demonstrated that it possessed a better effect than 
the parental natural compound DET on inhibiting the proliferation of a panel of melanoma 
cells with different genetic backgrounds. In vitro mechanistic studies suggested that 
DETD-35 acted through inducing cell apoptosis while vemurafenib mainly caused G1-phase 
cell cycle arrest in A375 cells. Notably, treatment with a combination of DETD-35 and 
vemurafenib not only induced apoptosis (increased in cleaved PARP expression and 
caspase-3 activity) but also caused G1-phase cell cycle arrest (increased p27 expression and 
suppressed cyclin D1 expression) in A375 cells. These data suggest the synergistic or 
complementary effect of the compound-drug combination, resulting in better inhibitory 
effects on colony formation and induction of more significant apoptosis in melanoma cells 
compared to compound or drug treatment alone. When anti-tumor growth activity was 
evaluated in vivo in parallel with FDA approved drug vemurafenib against BRAFV600E 
mutant melanoma, DETD-35 showed comparable bioefficacy. Furthermore, the compound-
drug combination showed statistically similar in vivo bioefficacy as a single compound 
treatment in which the treatment frequency of the compound-drug combination was only 
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half of the single compound administration frequency. These data suggested that DETD-35 
possesses both therapeutic and adjuvant activity against BRAFV600E mutant melanoma.
Resistance to vemurafenib therapy is mainly due to reactivation of MEK-ERK signaling in 
cells. In addition, activated RTK-driven alternative mechanisms such as the PI3K-Akt 
survival pathway also contributed to resistance to vemurafenib (9). Furthermore, Girotti and 
colleagues recently showed that EGFR-SRC family kinase (SFK)-STAT3 signaling is 
upregulated in vemurafenib resistant cells (34). Consistent with those previous studies, we 
showed the reactivation of phosphorylated forms of Src, MEK, ERK, Akt and STAT-3 in our 
in-house established resistance cell line A375-R. DETD-35 inhibited the reactivation of the 
proteins in the resistance cells in the same way as observed with the positive control MEK 
inhibitor. Interestingly, we observed that MEKi overcame acquired vemurafenib resistance 
by restoring the expression of p27 and inhibiting cyclin D1 that led to G1-phase cell-cycle 
arrest in the cells. In contrast, DETD-35 displayed a different mechanism to the MEK 
inhibitor, sensitizing vemurafenib to inhibit proliferative capability and enhance apoptosis of 
A375-R cells in xenograft mice. Moreover, DETD-35 also sensitized vemurafenib to inhibit 
intrinsic resistance tumor (A2058 xenograft) growth in mice. These data indicated the novel 
effect of DETD-35 in circumvention of both acquired and intrinsic vemurafenib resistant 
melanoma growth in mice.
Recent studies have shown multiple vemurafenib resistance mechanisms between patients, 
within patients and even within the same tumor biopsy (35, 36). It is therefore anticipated 
that multiple pathway inhibition combined with vemurafenib will achieve durable clinical 
control of BRAFV600E melanoma (35, 36). In our study, we showed that DETD-35 could 
deregulate multiple signaling molecules including MEK-ERK, Akt, and STAT3 in 
vemurafenib resistant melanoma cells A375-R, as shown in the schematic model 
(Supplementary Fig. S4), which supports, at least in part, the novel pharmacological activity 
of the new compound DETD-35. The complementary and synergistic activities of DETD-35 
and vemurafenib against BRAFV600E mutant melanoma and acquired vemurafenib 
resistance melanoma growth in mice suggested a novel strategy for the management of late 
stage BRAFV600E melanoma by using DETD-35 as a direct therapy or an adjuvant agent of 
vemurafenib.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
DETD-35 shows synergism with vemurafenib in vitro. A, B and C, A375 melanoma cells 
were treated with the indicated concentrations of PLX4032, DETD-35 and PLX4032***35 
for 72 h, respectively. Cell viability was determined using MTT assay. D, compound-drug 
combination study using CalcuSyn software. CI < 1 indicates synergism; CI = 1 indicates 
additive effect; CI > 1 indicates antagonism between the two compounds tested. E, top: 
colony formation assay showing long-term (21-day treatment) anti-proliferative effects of 
PLX4032, DETD-35 and DET against A375 cells. Crystal violet stained cells are shown. 
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Bottom: quantification of the crystal violet absorbance at 595 nm after 21 days of treatment. 
Data are mean ± SEM, n = 4. Means without a common letter differ, P < 0.05. F, cell-cycle 
analysis, cells were treated with the indicated concentrations of compounds for 24 h. After 
fixation, cells were stained with propidium iodide and analyzed by flow cytometry. G, 
combination of DETD-35 or DET with PLX4032 increased levels of apoptosis in A375 
melanoma cells. Cells were treated with the indicated concentrations of the compounds for 
72 h. Apoptosis status in cells was measured by Annexin V/FITC plus propidium iodide 
double staining and flow cytometry. Top: Representative quadrant diagrams showing cell 
distribution in Q1 (early apoptosis), Q2 (apoptosis), Q3 (live), and Q4 (dead). Bottom: 
apoptotic fraction was calculated by adding distribution percentage in Q1, Q2 and Q4 
together. Data are mean ± SEM, n = 3. Means without a common letter differ, P < 0.05.
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Figure 2. 
DETD-35 suppresses MEK-ERK signaling and induces apoptosis in A375 melanoma cells. 
A, cells were treated with indicated concentrations of the compounds for 16 h before lysis. 
Cell lysates were subjected to western blotting against the specific antibodies indicated, and 
actin was used as an internal or loading control. Quantification of specific protein 
expression, which was normalized to actin first followed by comparison of the fold-change 
within different treatments to vehicle treatment. B, cells were treated with indicated 
concentrations of the compounds for 72 h, caspase 3 activity was determined by measuring 
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cleavage of a fluorogenic substrate using flow cytometry (RFU: relative fluorescence units). 
Data are mean ± SEM, n = 3. Means without a common letter differ, P < 0.05.
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Figure 3. 
DETD-35 inhibits BRAFV600E mutant melanoma growth in vivo. NOD/SCID mice bearing 
A375 xenografts were treated with vehicle, PLX4032 (20 mg/kg/day), DETD-35 or DET (20 
mg/kg/every two days), and a compound-drug combination with alternate administration of 
DETD-35 or DET (20 mg/kg/every four days) plus PLX4032 (20 mg/kg/every two days), 
when tumor volume reached around 50 mm3. A, representative tumor tissues isolated from 
each treatment group. B, tumor volume was measured every three days and plotted as mean 
± SEM. C, the weight of the dissected tumors from each treatment group. Data are mean ± 
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SEM, n = 8. Means without a common letter differ, P < 0.05. D, top: representative 
immunohistochemistry images of tumor tissues with positive staining of phospho-MEK, 
phospho-ERK1/2, Ki-67, cleaved caspase-3 and cleaved PARP (brownish color) and nuclear 
(blue color) by hematoxylin staining are shown (Scale bar: 50 µm). Bottom: quantification 
of phospho-MEK, phospho-ERK1/2, Ki-67, cleaved caspase-3 and cleaved PARP positive 
stained cells, Data are mean ± SEM, n = 3. Means without a common letter differ, P < 0.05.
Feng et al. Page 20
Mol Cancer Ther. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
DETD-35 overcomes acquired vemurafenib resistance in vitro. A, B and C, A375-R cells 
were treated with indicated concentrations of PLX4032, DETD-35 and DET for 72 h. Cell 
viability was determined using MTT assay. D, top: colony formation assay showing long-
term (21-day treatment) anti-proliferative effects of PLX4032, DETD-35 and DET against 
A375-R cells. Crystal violet stained cells are shown. Bottom: quantification of the crystal 
violet absorbance at 595 nm after 21 days of treatment. Data are mean ± SEM, n = 4. Means 
without a common letter differ, P < 0.05. E, A375-R cells were treated with the indicated 
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concentrations of compounds for 16 h before lysis. Cell lysates were subjected to western 
blotting using the specific antibodies indicated, and actin was used as an internal or loading 
control. Quantification of specific protein expression, which was normalized to actin first 
followed by comparison of the fold change within different treatments to vehicle treatment.
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Figure 5. 
DETD-35 overcomes both intrinsic and acquired vemurafenib resistance in mice. NOD/
SCID mice bearing A375-R and A2058 xenografts were treated with vehicle, PLX4032 (75 
mg/kg/day), DETD-35 or DET (20 mg/kg/every two days), and a compound-drug 
combination with alternate administration of DETD-35 or DET (20 mg/kg/every two days) 
and PLX4032 (75 mg/kg/every two days), when tumor volume reached around 50 mm3. A, 
representative tumor tissues isolated from A375-R xenograft. B, tumor volume of A375-R 
xenograft was measured every three days and plotted as mean ± SEM. C, the weight of the 
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dissected tumors from A375-R xenograft. D, tumor volume of A2058 xenograft was 
measured every three days and plotted as mean ± SEM. E, the weight of the dissected 
tumors from A2058 xenograft. Data are mean ± SEM, n = 8. Means without a common letter 
differ, P < 0.05. F, top: representative immunohistochemistry images of A375-R tumor for 
positive staining of phospho-Src, phospho-MEK, phospho-ERK1/2, phospho-Akt, Ki-67, 
cleaved caspase-3, and cleaved PARP (Scale bar: 50 µm). Bottom: quantification of 
phospho-Src, phospho-MEK, phospho-ERK1/2, phospho-Akt, Ki-67, cleaved caspased-3, 
and cleaved PARP positive stained cells from tumor tissue sections of A375-R xenograft 
study. Data are mean ± SEM, n = 3. Means without a common letter differ, P < 0.05.
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Figure 6. 
DETD-35 induces oxidative stress to trigger apoptosis in A375 and A375-R cells. A and B, 
A375 cells and A375-R cells, respectively, were pretreated with or without NAC for 1 h 
followed by treatment with DETD-35 or DET at the indicated concentrations for 72 h. Cell 
viability was determined using MTT assay. C, top: reactive oxygen species (ROS) 
generation in A375 cells and A375-R cells treated with DETD-35 and DET alone or 
pretreated with NAC for 1 h followed by compound treatment for 2 h. Flow cytometry and 
green fluorescent dye (ROS detection probe) were used in this experiment. Bottom: 
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quantification of the generated ROS in the cells under the same treatment as top panel. Data 
are mean ± SEM, n = 4. Means without a common letter differ, P < 0.05. D, cell lysates from 
A375 and A375-R cells pretreated with or without NAC for 1 h followed by treatment with 
2.5 µM DETD-35 and 5 µM DET at the indicated times were collected and subjected to 
western blotting using the specific antibodies indicated, and actin was used as an internal or 
loading control.
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